'Rule-of-Five' Author Christopher Lipinski Joins Advisory Board of FlexX Developer BioSolveIT.

SANKT AUGUSTIN, Germany -- BioSolveIT, known for its high impact drug design software, has succeeded in winning renowned scientist Christopher A. Lipinski for its Scientific Advisory Board.

This landmark reinforcement further strengthens the company's focus on application-centered software. Dr. Christian Lemmen, CEO of BioSolveIT, is delighted with Dr. Lipinski's appointment: "Chris Lipinski will have a tremendous impact on our mission to supply top-flight software. With his experience we have a strong advocate for the needs of the application scientists on board. It will help us focus on the application and applicability of our technology".

In 1997, Berkeley alumnus Lipinski, who recently retired as Senior Research Fellow at Pfizer Global R&D, invented the groundbreaking "Rule-of-Five" to assess the drug-likeliness of a given molecule. His seminal contribution to the scientific world has been cited over 1000 times to date, is included in textbooks, and is in widespread use in the everyday drug development business. BioSolveIT announced that property calculations such as proposed by Dr. Lipinski are now an integral part of FlexX docking calculations, facilitating for example selections based on docking score and the "Rule-of-Five" to further improve the virtual screening performance of its software.

Professor Hugo Kubinyi, himself a longstanding member of BioSolveIT's Advisory Board, is very pleased with the development: "I have known Chris for years. Not only is he the perfect choice as advisor for this company of young, enthusiastic and very talented people, but also a lot of fun to work with. Chris's extensive experience and the visionary spirit of BioSolveIT are the very ingredients for an extremely fruitful collaboration."

Valuable scientific software should seamlessly integrate in a workflow of tools and experiments to help solve the bigger problems. Dr. Lipinski says: "When invited to join BioSolveIT's Advisory Board, I was immediately excited at the prospect of contributing my knowledge about the drug discovery process. Yes, I think I can help them optimize the perception of the needs of integration and further development of their cutting-edge software in concert with other experimental approaches and general drug discovery technology. Software plays an increasingly important role, and FlexX is certainly one of the most established docking tools on the market. The tool has already proved invaluable in driving drug design forward in numerous cases. It will be my pleasure to take part in further writing BioSolveIT's success story, and I look forward to stimulating and enjoyable cooperation."

BioSolveIT also develops and customizes software for the specific needs of users in the pharmaceutical industry. The FlexX developer recently became independent from its distribution partner, enabling a more direct customer relationship and bringing its scientists into even closer contact with application aspects. Having worked for Pfizer for over two decades and contributed to the discovery of numerous drug candidates, Dr. Lipinski is well-acquainted with the demands of pharmaceutical companies. This experience will ensure novel approaches of both scientific interest and practical value.

BioSolveIT, the developer of FlexX, is a globally operating cheminformatics and bioinformatics software company. BioSolveIT provides superior custom software solutions for structure-based design, flexible molecular alignment, database searching, library design, and analysis. Its breakthrough computational technologies help to innovate pharmaceutical research - transforming ideas into success stories.

http://www.biosolveit.de